CJO meta‑analysis finds no COPD risk

- A Clinical Ophthalmology meta‑analysis of 9,718 patients assessed respiratory events after intravitreal anti‑VEGF injections and found no overall increased COPD risk across agents. - The pooled dataset included 9,718 patients but did note agent‑specific differences in lower respiratory outcomes that merit attention. - Commentators urged standardized respiratory adverse‑event reporting when choosing anti‑VEGF agents for patients with pulmonary disease. (x.com)